Found "Vaccines": 73 results
Sort by
Sort by
Last updated
Human Papillomavirus Vaccine introduction in low and middle Income countries guidance on the use of Cost-effectiveness models.(2011)
Human papillomavirus vaccine introduction in low and middle income countries: guidance on the use of cost-effectiveness models
Mark Jit1, Nadia Demarteau2†, Elamin Elbasha3†, Gary Ginsberg4†, Jane Kim5†, Naiyana Praditsitthikorn6†, Edina Sinanovic7† and Raymond Hutubessy8*
† Contributed equally
8
Economic Evaluation of Policy Options for Prevention and Control of Cervical Cancer in Thailand.(2011)
Economic Evaluation of Policy Options for Prevention and Control of Cervical Cancer in Thailand
Naiyana Praditsitthikorn,1,2 Yot Teerawattananon,1,3 Sripen Tantivess,1,3 Supon Limwattananon,3 Arthorn Riewpaiboon,2 Saibua Chichareon,4
Nantakan Ieumwananonthachai5 and Viroj Tangcharoensathien3
Systematic Review of Economic Evaluations of Preparedness Strategies and Interventions against Influenza Pandemics
Systematic Review of Economic Evaluations of Preparedness Strategies and Interventions against Influenza Pandemics.
Roma´n Pe´ rez Velasco1*, Naiyana Praditsitthikorn1, Kamonthip Wichmann1, Adun Mohara1, Surachai Kotirum1, Sripen Tantivess1, Constanza Vallenas2, Hande Harmanci2, Yot Teerawattanan
Cost-utility analysis of 10- and 13-valent pneumococcal conjugate vaccines: Protection at what price in the Thai context? (2013)
Cost-utility analysis of 10- and 13-valent pneumococcal conjugate vaccines: Protection at what price in the Thai context?
Wantanee Kulpenga, b, , , , Pattara Leelahavaronga, , Waranya Rattanavipaponga, , Vorasith Sornsrivichaib, , Henry C. Baggettc, , Aronrag Meeyaia, d, , , Warunee Punpaniche, ,
A learning experience from price negotiations for vaccines
Full text can be accessed from:
http://www.sciencedirect.com/science/article/pii/S0264410X14017058
Methodological Variation in Economic Evaluations Conducted in Low- and Middle- Income Countries: Information for Reference Case Development
Benjarin Santatiwongchai1, Varit Chantarastapornchit1*, Thomas Wilkinson2, Kittiphong Thiboonboon1, Waranya Rattanavipapong1, Damian G Walker3, Kalipso Chalkidou2, Yot Teerawattananon1
1 Health Intervention and Technology Assessment Program, Nonthaburi, Thailand, 2 NICE International,National Insti
Do Pneumococcal Conjugate Vaccines Represent Good Value for Money in a Lower- Middle Income Country? A Cost-Utility Analysis in the Philippines (2015)
Manuel Alexander Haasis1*, Joyce Anne Ceria1, Wantanee Kulpeng2,
Yot Teerawattananon2, Marissa Alejandria3
1 National Center for Pharmaceutical Access and Management (NCPAM), Department of Health, Manila,
Philippines, 2 Health Intervention and Technology Assessment Program (HITAP), Department of
What criteria do decision makers in Thailand use to set priorities for vaccine introduction? (2016)
Siriporn Pooripussarakul1, Arthorn Riewpaiboon1* , David Bishai2, Charung Muangchana3 and Sripen Tantivess4
Abstract
Background: There is a need to identify rational criteria and set priorities for vaccines. In Thailand, many licensed vaccines are being considering for introduction into the Ex
A Systematic Review of Economic Evaluation Methodologies Between Resource-Limited and Resource-Rich Countries: A Case of Rotavirus Vaccines (2016)
Kittiphong Thiboonboon1 , Benjarin Santatiwongchai1 ,Varit Chantarastapornchit1 , Waranya Rattanavipapong1 , Yot Teerawattananon1
Abstract
Background
For more than three decades, the number and influence of economic evaluations of healthcare interventions have been increasing and gaining atte
Essential medicines for universal health coverage (2016)
Veronika J Wirtz*, Hans V Hogerzeil*, Andrew L Gray*, Maryam Bigdeli, Cornelis P de Joncheere, Margaret A Ewen, Martha Gyansa-Lutterodt,
Sun Jing, Vera L Luiza, Regina M Mbindyo, Helene Möller, Corrina Moucheraud, Bernard Pécoul, Lembit Rägo, Arash Rashidian,
Dennis Ross-Degnan, Peter N Stephens,
10 / Page